Evidence map›Paper›PMID 36207986›Full record

ReviewCancer medicine2023

Implications of estrogen and its receptors in colorectal carcinoma.

Plabon Kumar Das, Joti Saha, Suja Pillai, Alfred K-Y Lam, Vinod Gopalan, Farhadul Islam

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Ribifolones A-H, New Macrocyclic Diterpenes fromMolecules (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Menopause and gastrointestinal health and disease.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Plabon Kumar DasDepartment of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh.
Joti SahaDepartment of Applied Chemistry and Chemical Engineering, University of Rajshahi, Rajshahi, Bangladesh.
Suja PillaiSchool of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Alfred K-Y LamSchool of Medicine & Dentistry, Griffith University, Gold Coast, Queensland, Australia.ORCID 0000-0003-2771-564X
Vinod GopalanSchool of Medicine & Dentistry, Griffith University, Gold Coast, Queensland, Australia.
Farhadul IslamDepartment of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh.ORCID 0000-0001-5262-4702
Griffith University · AUThe University of Queensland · AUUniversity of Rajshahi · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Estrogens have been implicated in the pathogenesis of various cancer types, including colorectal carcinoma (CRC). Estrogen receptors such as ERα and ERβ activate intracellular signaling cascades followed by binding to estrogen, resulting in important changes in cellular behaviors. The nuclear estrogen receptors, i.e. ERβ and ERα are responsible for the genomic actions of estrogens, whereas the other receptor, such as G protein-coupled estrogen receptor (GPER) regulates rapid non-genomic actions, which lead to secondary gene expression changes in cells. ERβ, the predominant estrogen receptor expressed in both normal and non-malignant colonic epithelium, has protective roles in colon carcinogenesis. ERβ may exert the anti-tumor effect through selective activation of pro-apoptotic signaling, increasing DNA repair, inhibiting expression of oncogenes, regulating cell cycle progression, and also by changing the micro-RNA pool and DNA-methylation. Thus, a better understanding of the underlying mechanisms of estrogen and its receptors in CRC pathogenesis could provide a new horizon for effective therapeutic development. Furthermore, using synthetic or natural compounds as ER agonists may induce estrogen-mediated anti-cancer activities against colon cancer. In this study, we report the most recent pre-clinical and experimental evidences related to ERs in CRC development. Also, we reviewed the actions of naturally occurring and synthetic compounds, which have a protective role against CRC development by acting as ER agonist.

Indexed as

Colorectal NeoplasmsReceptors, EstrogenEstrogen Receptor alphaEstrogen Receptor betaEstrogensHumansReceptors, G-Protein-CoupledEstrogen Receptor alphaEstrogen Receptor betaEstrogensReceptors, EstrogenReceptors, G-Protein-Coupledchemotherapy, targeted therapycolorectal carcinomaestrogenestrogen receptors

Identifiers

PMID36207986
PMCPMC9972078
OpenAlexW4303628897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.